Advisor Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Advisor Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,763	Closed	-$173K	–	5204
2017 Q4	$173K	Buy	3,763 +1,304	+53%	+$65K	﹤0.01%	2131
2017 Q3	$109K	Buy	2,459 +1,439	+141%	+$49.1K	﹤0.01%	2335
2017 Q2	$31K	Sell	1,020 -215	-17%	-$5.3K	﹤0.01%	3185
2017 Q1	$27K	Buy	1,235 +200	+19%	+$4.29K	﹤0.01%	3175
2016 Q4	$19K	Sell	1,035 -2,780	-73%	-$68K	﹤0.01%	3260
2016 Q3	$115K	Buy	3,815 +1,296	+51%	+$40.3K	﹤0.01%	1907
2016 Q2	$95K	Buy	+2,519	New	+$105K	﹤0.01%	1967

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Advisor Group's JUNO Position: Q1 2018 in Review

Advisor Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 3,763 shares — an estimated $173K sold.

Advisor Group first reported a position in JUNO in Q2 2016 and held it in 7 quarters. The position peaked at $173K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Advisor Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Advisor Group sold 3,763 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $173K.
Advisor Group first reported a position in Juno Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
Advisor Group's Juno Therapeutics, Inc. position peaked at $173K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Advisor Group's 13F filing for Q1 2018, filed 15 May 2018.